Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to treat type 2 diabetes. Novo's drugs Ozempic and Wegovy are household names ...

Even as Novo Nordisk and Eli Lilly found themselves unable to fully serve demand, they still brought in billions of dollars ...

A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...

The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the ...

Pharmaceutical executives and public health experts have warned that Robert F Kennedy jnr’s influence over Donald Trump could ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

That may leave some Americans to question whether they'll find their local stores, banks, post offices, DMV and other services open on November 5. At the same time, some schools are closed on Election ...

Novo Nordisk is paying $55 million upfront to secure ... In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use. The launch environment ...

CENTRAL GOVERNMENT FUNDS: Social welfare would account for the largest portion of the NT$3.33 trillion budget, followed by spending on education, tech and culture ...